Search

Your search keyword '"Ariën, Kevin"' showing total 600 results

Search Constraints

Start Over You searched for: Author "Ariën, Kevin" Remove constraint Author: "Ariën, Kevin" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
600 results on '"Ariën, Kevin"'

Search Results

1. Humoral immunity to SARS-CoV-2 in kidney transplant recipients and dialysis patients: IgA and IgG patterns unraveled after SARS-CoV-2 infection and vaccination

2. COVID-19 seroprevalence cohort survey among health care workers and their household members in Kinshasa, DR Congo, 2020–2022

5. Fatal meningoencephalitis associated with Ebola virus persistence in two survivors of Ebola virus disease in the Democratic Republic of the Congo: a case report study

6. Potential determinants of the decline in mpox cases in Belgium: A behavioral, epidemiological and seroprevalence study

8. Hybrid Immunity Overcomes Defective Immune Response to COVID-19 Vaccination in Kidney Transplant Recipients

12. Chikungunya fever

14. Head-to-head comparison of diagnostic accuracy of four Ebola virus disease rapid diagnostic tests versus GeneXpert® in eastern Democratic Republic of the Congo outbreaks: a prospective observational study

15. Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients

16. Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium

17. Characteristics of confirmed mpox cases among clinical suspects: A prospective single-centre study in Belgium during the 2022 outbreak

18. Field performance of three Ebola rapid diagnostic tests used during the 2018–20 outbreak in the eastern Democratic Republic of the Congo: a retrospective, multicentre observational study

19. Five accelerated schedules for the tick-borne encephalitis vaccine FSME-Immun® in last-minute travellers: an open-label, single-centre, randomized controlled pilot trial.

20. Importance of anti-SARS-CoV-2 assay antigenic composition as revealed by the results of the Belgian external quality assessment (EQA) scheme

25. Potential determinants of the decline in mpox cases in Belgium:A behavioral, epidemiological and seroprevalence study

26. Antibodies against medically relevant arthropod-borne viruses in the ubiquitous African rodent Mastomys natalensis.

29. Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients

30. Revisiting a COVID-19 seroprevalence cohort survey among health care workers and their household members in Kinshasa, DR Congo, 2020-2022

31. Hybrid immunity overcomes defective immune response to COVID-19 vaccination in kidney transplant recipients

35. Arbovirus researchers unite: expanding genomic surveillance for an urgent global need

36. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial

37. Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial

39. Head-to-head comparison of diagnostic accuracy of four Ebola virus disease rapid diagnostic tests versus GeneXpert® in eastern Democratic Republic of the Congo outbreaks: a prospective observational study

40. Validation of a Reporter Cell Line for Flavivirus Inhibition Assays

41. Data from Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer

42. Figure S1 from Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer

43. Supplementary Tables S1-S2 from Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer

44. Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults

45. SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations.

46. Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults.

47. Essentials of filoviral load quantification

49. Inactivation of SARS-CoV-2 and Other Enveloped and Non-Enveloped Viruses with Non-Thermal Plasma for Hospital Disinfection

50. Characteristics of confirmed mpox cases among clinical suspects: A prospective single-centre study in Belgium during the 2022 outbreak

Catalog

Books, media, physical & digital resources